Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create medicines for people living with psychiatric and neurological conditions. Co.'s pipeline is built on the therapeutic potential of its lead product candidate, KarXT, an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. KarXT is Co.'s proprietary product candidate that combines xanomeline with trospium to preferentially stimulate muscarinic receptors in the CNS. KarXT is for the treatment of acute psychosis in patients with schizophrenia. Co. is also developing KarXT as a potential treatment for dementia-related psychosis and pain. The KRTX stock yearly return is shown above.
The yearly return on the KRTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the KRTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|